These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10601072)

  • 21. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ovarian hyperstimulation syndrome (OHSS): how much do we really know about it?
    Tsirigotis M; Craft I
    Eur J Obstet Gynecol Reprod Biol; 1994 Jun; 55(3):151-5. PubMed ID: 7958157
    [No Abstract]   [Full Text] [Related]  

  • 23. C-reactive protein response is higher in early than in late ovarian hyperstimulation syndrome.
    Korhonen KV; Savolainen-Peltonen HM; Mikkola TS; Tiitinen AE; Unkila-Kallio LS
    Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():162-168. PubMed ID: 27865939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coasting may reduce the severity of the ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome.
    Ohata Y; Harada T; Ito M; Yoshida S; Iwabe T; Terakawa N
    Gynecol Obstet Invest; 2000; 50(3):186-8. PubMed ID: 11014952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe OHSS: how many cases are preventable?
    Egbase PE
    Hum Reprod; 2000 Jan; 15(1):8-10. PubMed ID: 10611179
    [No Abstract]   [Full Text] [Related]  

  • 26. Ovarian hyperstimulation syndrome: definition, incidence, and classification.
    Zivi E; Simon A; Laufer N
    Semin Reprod Med; 2010 Nov; 28(6):441-7. PubMed ID: 21082501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Number of oocytes retrieved and resulting pregnancy. Risk factors for ovarian hyperstimulation syndrome.
    Reljic M; Vlaisavljević V; Gavrić V; Kovacic B
    J Reprod Med; 1999 Aug; 44(8):713-8. PubMed ID: 10483542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ovarian hyperstimulation syndrome due to exogenous gonadotropin administration.
    Bider D; Menashe Y; Oelsner G; Serr DM; Mashiach S; Ben-Rafael Z
    Acta Obstet Gynecol Scand; 1989; 68(6):511-4. PubMed ID: 2520805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased erythrocyte aggregation in ovarian hyperstimulation syndrome: a possible contributing factor in the pathophysiology of this disease.
    Levin I; Gamzu R; Hasson Y; Lessing JB; Amit A; Shapira I; Berliner S; Almog B
    Hum Reprod; 2004 May; 19(5):1076-80. PubMed ID: 15044400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ovarian hyperstimulation syndrome.
    Avecillas JF; Falcone T; Arroliga AC
    Crit Care Clin; 2004 Oct; 20(4):679-95, ix. PubMed ID: 15388196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe ovarian hyperstimulation syndrome modifies early maternal serum beta-human chorionic gonadotropin kinetics, but obstetrical and neonatal outcomes are not impacted.
    Choux C; Barberet J; Ginod P; Cottenet J; Bruno C; Benzénine E; Sagot P; Fauque P
    Fertil Steril; 2017 Oct; 108(4):650-658.e2. PubMed ID: 28911926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elective frozen-thawed embryo transfer (FET) in women at risk for ovarian hyperstimulation syndrome.
    Zech J; Brandao A; Zech M; Lugger K; Neururer S; Ulmer H; Ruttmann-Ulmer E
    Reprod Biol; 2018 Mar; 18(1):46-52. PubMed ID: 29279182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention and management of ovarian hyperstimulation syndrome.
    Vlahos NF; Gregoriou O
    Ann N Y Acad Sci; 2006 Dec; 1092():247-64. PubMed ID: 17308149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction? A systematic review and meta-analysis.
    Baumgarten M; Polanski L; Campbell B; Raine-Fenning N
    Hum Fertil (Camb); 2013 Sep; 16(3):168-74. PubMed ID: 24047196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of ovarian hyperstimulation syndrome in women undergoing in vitro fertilization.
    Kahnberg A; Enskog A; Brännström M; Lundin K; Bergh C
    Acta Obstet Gynecol Scand; 2009; 88(12):1373-81. PubMed ID: 19878052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renin-angiotensin system activation during severe OHSS: cause or effect?
    Manno M; Tomei F
    Fertil Steril; 2008 Feb; 89(2):488. PubMed ID: 18275884
    [No Abstract]   [Full Text] [Related]  

  • 37. [Incidence of ovarian hyperstimulation syndrome in in-vitro-fertilization treatment over a period of 11 years].
    Niederberger V; Rottensteiner-Grohsmann C; Turnheim K; Obruca A; Brunner M; Feichtinger W
    Wien Med Wochenschr; 1995; 145(23):642-5. PubMed ID: 8578756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential health hazards of assisted reproduction. Problems facing the clinician.
    Amso NN
    Hum Reprod; 1995 Jul; 10(7):1628-30. PubMed ID: 8582950
    [No Abstract]   [Full Text] [Related]  

  • 39. Ovarian hyperstimulation syndrome prevention strategies: use of gonadotropin-releasing hormone antagonists.
    Griesinger G
    Semin Reprod Med; 2010 Nov; 28(6):493-9. PubMed ID: 21082508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thyroid function after controlled ovarian hyperstimulation in women with and without the hyperstimulation syndrome.
    Poppe K; Unuane D; D'Haeseleer M; Tournaye H; Schiettecatte J; Haentjens P; Velkeniers B
    Fertil Steril; 2011 Jul; 96(1):241-5. PubMed ID: 21565336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.